PACB
Pacific Biosciences of California, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+43/100
Last price
2.69
▼ 0.18 (6.24%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.97
Prev close
2.87
Day high
3.44
Day low
2.44
Volume
47.10M
Market cap
$839.24M
P/E (TTM)
—
52W range
1.07 – 3.44
Day trading desk
Gap from prior close
+3.46%
Prior close 2.87
VWAP
2.71
-0.68% from price
Relative volume
9.54×
Unusually busy
Session range
41.07%
2.43 – 3.43
Position in range
26%
Near session low
ATR (14D)
0.26
9.71% of price
Prior day high
2.92
PDH
Prior day low
2.51
PDL
Bid / ask spread
—
Quote not published
Session volume
93.04M
Avg 9.76M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+47.54%
+45.6%
1M
+100.00%
+98.8%
3M
+80.00%
+75.5%
6M
+87.50%
+69.3%
YTD
+44.39%
+30.1%
1Y
+81.21%
+64.8%
3Y
-67.66%
-149.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PACB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+519.69K
Net buying
Buy transactions
2
546.60K shares
Sell transactions
1
26.91K shares
Net transactions
+3
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
27.70M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | VAN OENE MARK D Chief Executive Officer |
SELL | 26.91K | $30.41K | Direct |
| Aug 10, 26 | VAN OENE MARK D Chief Executive Officer |
STOCK | 489.13K | $0 | Direct |
| Apr 8, 26 | GIBSON CHRISTOPHER C. Director |
STOCK | 57.47K | $0 | Direct |
| Apr 1, 26 | GIBSON JAMES R II Chief Financial Officer |
SELL | 88.19K | $120.81K | Direct |
| Mar 3, 26 | GIBSON CHRISTOPHER C. Director |
STOCK | 53.91K | $0 | Direct |
| Mar 3, 26 | VAN OENE MARK D Chief Operating Officer |
SELL | 6.50K | $9.85K | Direct |
| Mar 3, 26 | FARMER MICHELE CPA Officer |
SELL | 2.98K | $4.51K | Direct |
| Mar 3, 26 | HENRY CHRISTIAN O Chief Executive Officer |
SELL | 12.50K | $18.92K | Direct |
| Feb 27, 26 | FARMER MICHELE CPA Officer |
STOCK | 89.83K | $0 | Direct |
| Feb 27, 26 | HENRY CHRISTIAN O Chief Executive Officer |
STOCK | 920.81K | $0 | Direct |
| Feb 27, 26 | GIBSON JAMES R II Chief Financial Officer |
STOCK | 333.85K | $0 | Direct |
| Feb 27, 26 | VAN OENE MARK D Chief Operating Officer |
STOCK | 500.00K | $0 | Direct |
| Feb 18, 26 | VAN OENE MARK D Chief Operating Officer |
SELL | 184.90K | $294.32K | Direct |
| Feb 18, 26 | FARMER MICHELE CPA Officer |
SELL | 50.17K | $79.86K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FARMER MICHELE CPA |
Officer | 305.95K | Sale |
GIBSON CHRISTOPHER C. |
Director | 111.39K | Stock Award(Grant) |
GIBSON JAMES R II |
Chief Financial Officer | 1.25M | Sale |
HENRY CHRISTIAN O |
Chief Executive Officer | 3.58M | Sale |
SMITH CHRISTOPHER MICHAEL |
Director | 54.10K | Stock Award(Grant) |
VAN OENE MARK D |
Chief Executive Officer | 2.71M | Sale |
Fundamentals
Market cap$839.24M
Enterprise value$1.31B
Revenue (TTM)$159.27M
Gross profit$46.86M
EBITDA$199.18M
Net income$-131.39M
EPS (TTM)$-0.40
Free cash flow$291.64M
Total cash$236.87M
Total debt$709.13M
Book value / share$-0.11
Shares outstanding310.83M
Float304.01M
Short % of float18.08%
Dividend yield0.00%
Beta (5Y)2.19
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.62
PEG ratio—
Price / sales—
Price / book—
EV / revenue8.23
EV / EBITDA6.59
Gross margin29.42%
Operating margin-114.36%
Profit margin-82.49%
Return on equity-929.32%
Return on assets-14.07%
Debt / equity—
Current ratio4.92
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $160.00M | $154.01M | $200.52M | $128.30M | +3.9% |
| Operating revenue | $160.00M | $154.01M | $200.52M | $128.30M | +3.9% |
| Cost of revenue | $114.22M | $116.73M | $147.74M | $79.27M | -2.1% |
| Gross profit | $45.78M | $37.28M | $52.78M | $49.03M | +22.8% |
| Research & development | $97.31M | $134.92M | $187.17M | $193.00M | -27.9% |
| Selling, general & admin | $141.49M | $175.02M | $169.82M | $160.85M | -19.2% |
| Total operating expense | $603.34M | $327.94M | $363.14M | $353.85M | +84.0% |
| Operating income | -$557.56M | -$290.66M | -$310.37M | -$304.82M | -91.8% |
| Net interest income | -$6.95M | -$13.41M | -$14.34M | -$14.69M | +48.2% |
| Pre-tax income | -$546.06M | -$309.54M | -$318.16M | -$314.25M | -76.4% |
| Tax provision | $318.00K | $316.00K | -$11.42M | $0 | +0.6% |
| Net income | -$546.38M | -$309.85M | -$306.74M | -$314.25M | -76.3% |
| Net income to common | -$546.38M | -$309.85M | -$306.74M | -$314.25M | -76.3% |
| Basic EPS | -1.82 | -1.12 | -1.21 | -1.40 | -62.5% |
| Diluted EPS | -1.82 | -1.58 | -1.21 | -1.40 | -15.2% |
| EBIT | -$539.10M | -$296.12M | -$303.82M | -$299.56M | -82.1% |
| EBITDA | -$152.69M | -$242.77M | -$277.28M | -$282.24M | +37.1% |
| Basic shares | 299.96M | 274.49M | 253.63M | 224.55M | +9.3% |
| Diluted shares | 299.96M | 288.37M | 253.63M | 224.55M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.71M | $55.37M | $179.91M | $325.09M | — | +15.1% |
| Cash & short-term investments | $279.51M | $389.93M | $631.42M | $772.32M | — | -28.3% |
| Accounts receivable | $35.45M | $27.52M | $36.62M | $18.79M | — | +28.8% |
| Inventory | $49.28M | $58.76M | $56.68M | $50.38M | — | -16.1% |
| Total current assets | $375.05M | $495.68M | $742.05M | $852.07M | — | -24.3% |
| Property, plant & equipment | $65.84M | $46.60M | $69.03M | $81.34M | — | +41.3% |
| Goodwill & intangibles | $332.88M | $707.33M | $919.25M | $820.22M | — | -52.9% |
| Total assets | $784.08M | $1.26B | $1.75B | $1.77B | — | -37.8% |
| Total current liabilities | $72.83M | $66.30M | $95.03M | $263.33M | — | +9.9% |
| Current debt | — | — | $490.00K | $1.84M | $1.61M | — |
| Long-term debt | $645.38M | $647.49M | $892.24M | $896.68M | — | -0.3% |
| Total debt | $702.42M | $672.43M | $933.93M | $948.48M | — | +4.5% |
| Total liabilities | $778.73M | $753.85M | $1.04B | $1.20B | — | +3.3% |
| Retained earnings | -$2.70B | -$2.15B | -$1.84B | -$1.53B | — | -25.4% |
| Shareholder equity | $5.35M | $506.59M | $701.30M | $562.90M | — | -98.9% |
| Working capital | $302.22M | $429.38M | $647.02M | $588.74M | — | -29.6% |
| Net tangible assets | -$327.54M | -$200.74M | -$217.94M | -$257.31M | — | -63.2% |
| Shares issued | 301.96M | 294.42M | 267.74M | 226.50M | — | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$546.38M | -$309.85M | -$306.74M | -$314.25M | -76.3% |
| Depreciation & amortisation | $386.41M | $53.35M | $26.53M | $17.32M | +624.3% |
| Stock-based compensation | $41.67M | $71.04M | $72.12M | $78.61M | -41.3% |
| Change in working capital | $4.44M | -$40.58M | -$58.96M | -$53.97M | +110.9% |
| Operating cash flow | -$111.21M | -$206.06M | -$259.17M | -$263.21M | +46.0% |
| Capital expenditure | -$7.71M | -$6.19M | -$8.84M | -$16.93M | -24.7% |
| Investing cash flow | $115.45M | $124.00M | $4.60M | $116.08M | -6.9% |
| Financing cash flow | $3.43M | -$42.99M | $108.89M | $9.62M | +108.0% |
| Free cash flow | -$118.92M | -$212.25M | -$268.02M | -$280.14M | +44.0% |
| End cash position | $65.26M | $57.59M | $182.63M | $325.09M | +13.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $39.01M | $37.18M | $44.65M | $38.44M | $39.77M | +4.9% |
| Operating revenue | $39.01M | $37.18M | $44.65M | $38.44M | $39.77M | +4.9% |
| Cost of revenue | $26.37M | $24.34M | $28.08M | $22.54M | $25.08M | +8.3% |
| Gross profit | $12.64M | $12.84M | $16.57M | $15.90M | $14.68M | -1.6% |
| Research & development | $23.02M | $19.61M | $22.88M | $22.85M | $22.53M | +17.4% |
| Selling, general & admin | $33.39M | $31.15M | $34.05M | $31.10M | $36.17M | +7.2% |
| Total operating expense | $57.25M | $66.99M | $57.76M | $54.78M | $59.54M | -14.5% |
| Operating income | -$44.61M | -$54.15M | -$41.20M | -$38.88M | -$44.85M | +17.6% |
| Net interest income | -$2.11M | -$1.74M | -$1.74M | -$1.74M | -$1.74M | -21.3% |
| Pre-tax income | -$44.68M | -$8.09M | -$40.17M | -$37.62M | -$41.90M | -452.3% |
| Tax provision | $58.00K | $184.00K | $202.00K | $383.00K | $35.00K | -68.5% |
| Net income | -$44.74M | -$8.28M | -$40.37M | -$38.00M | -$41.93M | -440.7% |
| Net income to common | -$44.74M | -$8.28M | -$40.37M | -$38.00M | -$41.93M | -440.7% |
| Basic EPS | -0.14 | -0.03 | -0.13 | -0.13 | -0.14 | -366.7% |
| Diluted EPS | -0.14 | -0.03 | -0.13 | -0.13 | -0.14 | -366.7% |
| EBIT | -$42.57M | -$6.35M | -$38.43M | -$35.88M | -$40.16M | -570.3% |
| EBITDA | -$38.05M | -$2.28M | -$33.78M | -$31.48M | -$35.58M | -1,567.5% |
| Basic shares | 310.40M | 305.82M | 301.91M | 300.84M | 300.16M | +1.5% |
| Diluted shares | 310.40M | 305.82M | 301.91M | 300.84M | 300.16M | +1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $61.00M | $56.27M | $63.71M | $56.47M | $54.80M | +8.4% |
| Cash & short-term investments | $236.87M | $275.96M | $279.51M | $298.65M | $314.74M | -14.2% |
| Accounts receivable | $31.10M | $29.35M | $35.45M | $30.62M | $32.26M | +6.0% |
| Inventory | $61.08M | $51.02M | $49.28M | $53.15M | $53.84M | +19.7% |
| Total current assets | $338.64M | $369.52M | $375.05M | $394.24M | $413.40M | -8.4% |
| Property, plant & equipment | $67.30M | $65.22M | $65.84M | $64.71M | $66.61M | +3.2% |
| Goodwill & intangibles | $330.85M | $331.87M | $332.88M | $333.90M | $334.92M | -0.3% |
| Total assets | $751.85M | $782.37M | $784.08M | $803.16M | $825.47M | -3.9% |
| Total current liabilities | $68.81M | $65.36M | $72.83M | $63.21M | $59.75M | +5.3% |
| Long-term debt | $644.33M | $644.11M | $645.38M | $645.16M | $646.44M | +0.0% |
| Total debt | $706.13M | $703.39M | $702.42M | $700.08M | $699.22M | +0.4% |
| Total liabilities | $785.06M | $780.00M | $778.73M | $767.07M | $763.98M | +0.6% |
| Retained earnings | -$2.75B | -$2.70B | -$2.70B | -$2.65B | -$2.62B | -1.7% |
| Shareholder equity | -$33.21M | $2.37M | $5.35M | $36.09M | $61.49M | -1,503.8% |
| Working capital | $269.83M | $304.16M | $302.22M | $331.03M | $353.64M | -11.3% |
| Net tangible assets | -$364.06M | -$329.50M | -$327.54M | -$297.81M | -$273.44M | -10.5% |
| Shares issued | 310.81M | 310.49M | 301.96M | 301.85M | 300.35M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$44.74M | -$8.28M | -$40.37M | -$38.00M | -$41.93M | — | -440.7% |
| Depreciation & amortisation | $4.52M | $4.07M | $4.65M | $4.40M | $4.58M | — | +11.1% |
| Stock-based compensation | $9.26M | $4.46M | $9.59M | $10.98M | $11.89M | — | +107.7% |
| Change in working capital | -$5.99M | $3.17M | $7.49M | $3.21M | -$3.87M | — | -289.0% |
| Operating cash flow | -$35.58M | -$44.69M | -$19.07M | -$18.71M | -$29.38M | — | +20.4% |
| Capital expenditure | -$3.61M | -$8.04M | -$861.00K | — | -$550.00K | -$6.39M | +55.1% |
| Investing cash flow | $40.07M | $35.86M | $26.03M | $18.90M | $25.28M | — | +11.7% |
| Financing cash flow | $255.00K | $1.44M | $0 | $1.47M | $0 | — | -82.3% |
| Free cash flow | -$39.19M | -$52.73M | -$19.93M | -$18.62M | -$29.93M | — | +25.7% |
| End cash position | $62.61M | $56.27M | $65.26M | $58.30M | $56.63M | — | +11.3% |
Options analytics
Put / call volume
0.13
Call-heavy session
Put / call open interest
0.25
Positioning, not flow
Max pain
1.50
-44.4% from spot
ATM implied vol
131.3%
Nearest strike to spot
Skew (10% OTM)
+9.4%
Puts bid over calls
Call volume
7.79K
Contracts, this expiry
Put volume
991
Contracts, this expiry
Heaviest call OI
3.00
5.02K contracts
Heaviest put OI
2.00
2.39K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.13 | -0.14 | -10.4% |
| Mar 2026 | -0.13 | -0.12 | +8.7% |
| Dec 2025 | -0.13 | -0.12 | +10.8% |
| Sep 2025 | -0.14 | -0.12 | +15.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.13 | 7 | $39.49M | +2.7% |
| Next quarter | -0.13 | 7 | $43.07M | -3.5% |
| Current year | -0.52 | 7 | $158.77M | -0.8% |
| Next year | -0.42 | 7 | $183.73M | +15.7% |
Analyst targets & ownership
Mean target$2.16
High target$3.00
Low target$1.25
Implied upside-19.84%
Analyst count7
ConsensusBUY
Strong buy / Buy0 / 4
Hold3
Sell / Strong sell0 / 1
Held by insiders8.91%
Held by institutions55.48%
Institutions holding299
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.11
+27.29% from price
SMA 20
1.73
+56.02% from price
SMA 50
1.48
+82.58% from price
SMA 100
1.45
+84.95% from price
SMA 200
1.58
+70.59% from price
EMA 12
2.15
+24.91% from price
EMA 26
1.82
+48.09% from price
EMA 50
1.63
+65.40% from price
RSI (14)
79.9
Overbought
MACD (12,26,9)
0.34
Hist 0.14
ATR (14)
0.26
9.68% of price
Realised vol 30D
112.7%
Annualised
Bollinger upper
2.78
20, 2σ
Bollinger lower
0.68
20, 2σ
50 / 200 cross
Death
1.48 vs 1.58
Trend bias
Above 200
+70.59%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.36
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
112.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.4%
Peak to trough
Max drawdown 5Y
-97.0%
Peak to trough
ATR 14
0.26
9.68% of price
Beta (reported)
2.19
5Y monthly, from filing
Short interest
Shares short
48.89M
Prior 53.41M
Change vs prior
-8.5%
Shorts covering
% of float
18.08%
Elevated
% of shares out
15.73%
Against total outstanding
Days to cover
8.0
Crowded exit
Float
304.01M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 11, 26 | Barclays | MAINTAINED | Underweight | Underweight |
| Apr 14, 26 | Barclays | MAINTAINED | Underweight | Underweight |
| Mar 6, 26 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Dec 15, 25 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Nov 11, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Nov 10, 25 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Aug 11, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Jun 25, 25 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| May 15, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| May 15, 25 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Apr 10, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 25, 25 | Scotiabank | MAINTAINED | Sector Outperform | Sector Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-8 · 2026-08-07
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-09
Corporate Changes & Voting Matters
8-K · 2026-06-04
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-27
Proxy Statements
DEFA14A · 2026-05-22
Periodic Financial Reports
10-Q · 2026-05-08
Headlines
PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More Complicated
TIKR · 10h ago
Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training
MT Newswires · 12h ago
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
GlobeNewswire · 13h ago
Why PacBio (PACB) Stock Is Trading Up Today
StockStory · 1d ago
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Zacks · 4d ago
3 Biotech Stocks Put Traders Are Targeting Today
Schaeffer's Investment Research · 5d ago
Why Is PacBio (PACB) Stock Soaring Today
StockStory · 6d ago
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
StockStory · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.